Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab

Table 2

Results of HER2 protein status as determined by IHC and gene status as determined by FISH in breast cancer patients from the diagnostic series.

		FISH
Diagnostic series		Not amplified		Equivocal		Amplified		Total
IHC	0	22	100%	0	0%	0	0%	22	10%
	1+	30	77%	5	13%	4	10%	39	18%
	2+	82	61%	18	13%	34	25%	134	62%
	3+	0	0%	0	0%	21	100%	21	10%
	total	134	62%	23	11%	59	27%	216	100%